Cargando…
Embracing cancer immunotherapy with vital micronutrients
Immunotherapy is now commonly prescribed to cancer patients, but autoimmune-related adverse events are considerable. For severe, life-threatening side effects, cessation of therapy seems unavoidable, let alone intensive medical care required for patching up the adverse events. Even without serious a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479349/ https://www.ncbi.nlm.nih.gov/pubmed/34631438 http://dx.doi.org/10.5306/wjco.v12.i9.712 |
_version_ | 1784576235977834496 |
---|---|
author | Yuen, Raymond C-F Tsao, Shiu-Ying |
author_facet | Yuen, Raymond C-F Tsao, Shiu-Ying |
author_sort | Yuen, Raymond C-F |
collection | PubMed |
description | Immunotherapy is now commonly prescribed to cancer patients, but autoimmune-related adverse events are considerable. For severe, life-threatening side effects, cessation of therapy seems unavoidable, let alone intensive medical care required for patching up the adverse events. Even without serious adverse events, the response rates are too low and various combinatory regimens have been tried. However, toxicities are also added on, unless the adjuvant agents have remarkably few side effects. Actually, micronutrients are usually taken by a majority of cancer patients as nutritional support or to boost the immune function, let alone hoping to counteract treatment side effects. Recent studies have shown that combinations of micronutrients exert pleiotropic effects in controlling tumor growth and metastasis by modulating the tumor microenvironment, enhancing gut microbiota immune functions, and providing adjunct nutritional support to micronutrient deficient cancer patients. A higher than recommended dietary allowance micronutrient dose is proposed to reduce the toxic free radicals generated as a result of immunotherapy and tumor metabolism. This is not only helpful for managing treatment side effects but also enhancing treatment efficacy. As micronutrient supplementation is also useful to improve patients’ quality of life, prolong survival, and sustain compliance to immunotherapy, further investigations are mandatory. |
format | Online Article Text |
id | pubmed-8479349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-84793492021-10-08 Embracing cancer immunotherapy with vital micronutrients Yuen, Raymond C-F Tsao, Shiu-Ying World J Clin Oncol Review Immunotherapy is now commonly prescribed to cancer patients, but autoimmune-related adverse events are considerable. For severe, life-threatening side effects, cessation of therapy seems unavoidable, let alone intensive medical care required for patching up the adverse events. Even without serious adverse events, the response rates are too low and various combinatory regimens have been tried. However, toxicities are also added on, unless the adjuvant agents have remarkably few side effects. Actually, micronutrients are usually taken by a majority of cancer patients as nutritional support or to boost the immune function, let alone hoping to counteract treatment side effects. Recent studies have shown that combinations of micronutrients exert pleiotropic effects in controlling tumor growth and metastasis by modulating the tumor microenvironment, enhancing gut microbiota immune functions, and providing adjunct nutritional support to micronutrient deficient cancer patients. A higher than recommended dietary allowance micronutrient dose is proposed to reduce the toxic free radicals generated as a result of immunotherapy and tumor metabolism. This is not only helpful for managing treatment side effects but also enhancing treatment efficacy. As micronutrient supplementation is also useful to improve patients’ quality of life, prolong survival, and sustain compliance to immunotherapy, further investigations are mandatory. Baishideng Publishing Group Inc 2021-09-24 2021-09-24 /pmc/articles/PMC8479349/ /pubmed/34631438 http://dx.doi.org/10.5306/wjco.v12.i9.712 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Review Yuen, Raymond C-F Tsao, Shiu-Ying Embracing cancer immunotherapy with vital micronutrients |
title | Embracing cancer immunotherapy with vital micronutrients |
title_full | Embracing cancer immunotherapy with vital micronutrients |
title_fullStr | Embracing cancer immunotherapy with vital micronutrients |
title_full_unstemmed | Embracing cancer immunotherapy with vital micronutrients |
title_short | Embracing cancer immunotherapy with vital micronutrients |
title_sort | embracing cancer immunotherapy with vital micronutrients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479349/ https://www.ncbi.nlm.nih.gov/pubmed/34631438 http://dx.doi.org/10.5306/wjco.v12.i9.712 |
work_keys_str_mv | AT yuenraymondcf embracingcancerimmunotherapywithvitalmicronutrients AT tsaoshiuying embracingcancerimmunotherapywithvitalmicronutrients |